Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SEC CIK 1615258 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NATR | NATURES SUNSHINE PRODUCTS INC | 10% | 64.2K | — | $175.1K | 4 | 2021-04-12 | 2024-10-15 |
Most active insiders at NATR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 10% | $2.61M | — |
| 2 | Norman Daniel C | EVP, Pres, Asia | — | $759.4K |
| 3 | Yates Bryant J | EVP, Pres, Europe | — | $751.3K |
| 4 | Brower Nathan G | EVP, GC | — | $341.5K |
| 5 | Lanoy Jonathan David | SVP, CAO | — | $201.1K |
| 6 | Herbert Kevin R. | EVP, Pres, North America | — | $41.4K |
| 7 | Perkins Ruth Ann | EVP, CFO | — | — |
| 8 | Fuller Kevin Gregory | Gbl CMO | — | — |
| 9 | Jones Leslie Shane | EVP, CFO | — | — |
| 10 | Yang Rong | Dir | — | — |
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. made no open-market trades at NATR in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-10-17 | 2024-10-15 | NATR | NATURES SUNSHINE PRODUCTS INC | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.02 | -2,300 | 64.2K | -3% | -$29.9K |
| MI | 2024-10-15 | 2024-10-01+ | NATR | NATURES SUNSHINE PRODUCTS INC | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $13.33 | -10.9K | 76.0K | -13% | -$145.2K |
| I | 2024-10-15 | 2024-09-06 | NATR | NATURES SUNSHINE PRODUCTS INC | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | J - Other | $0.00 | +2,968 | 77.4K | +4% | $0 |
| MI | 2022-01-24 | 2021-04-12+ | NATR | NATURES SUNSHINE PRODUCTS INC | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | J - Other | $6.18 | +35.3K | 49.4K | +250% | +$218.0K |
Purchase Sale Sale after option exercise All abbreviations